Kura Oncology (KURA) Downgraded by BidaskClub

Kura Oncology (NASDAQ:KURA) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Friday.

A number of other research analysts also recently issued reports on the stock. Cann reiterated a “buy” rating and issued a $30.00 price target on shares of Kura Oncology in a research note on Friday, February 16th. Citigroup set a $28.00 price target on shares of Kura Oncology and gave the stock a “buy” rating in a research note on Friday, February 16th. Wedbush initiated coverage on shares of Kura Oncology in a research note on Tuesday, December 26th. They issued a “buy” rating and a $19.00 price target for the company. Zacks Investment Research upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Thursday, February 8th. Finally, Oppenheimer set a $18.00 price target on shares of Kura Oncology and gave the stock a “buy” rating in a research note on Monday, December 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $22.50.

How to Become a New Pot Stock Millionaire

Kura Oncology (NASDAQ:KURA) opened at $18.45 on Friday. Kura Oncology has a 12 month low of $5.90 and a 12 month high of $24.02. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.44 and a quick ratio of 9.44.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Monday, March 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). equities analysts expect that Kura Oncology will post -1.43 EPS for the current fiscal year.

Several large investors have recently modified their holdings of KURA. New York State Common Retirement Fund purchased a new stake in shares of Kura Oncology during the 2nd quarter worth approximately $142,000. MetLife Investment Advisors LLC purchased a new stake in shares of Kura Oncology during the 4th quarter worth approximately $155,000. American International Group Inc. lifted its position in shares of Kura Oncology by 42.0% during the 4th quarter. American International Group Inc. now owns 13,574 shares of the company’s stock worth $208,000 after buying an additional 4,012 shares during the last quarter. California State Teachers Retirement System purchased a new stake in shares of Kura Oncology during the 2nd quarter worth approximately $235,000. Finally, Virtus Fund Advisers LLC purchased a new stake in shares of Kura Oncology during the 4th quarter worth approximately $392,000. Institutional investors and hedge funds own 58.56% of the company’s stock.

WARNING: “Kura Oncology (KURA) Downgraded by BidaskClub” was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3299297/kura-oncology-kura-downgraded-by-bidaskclub.html.

Kura Oncology Company Profile

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

vSlice Tops 24-Hour Volume of $15,024.00
vSlice Tops 24-Hour Volume of $15,024.00
Brokerages Expect Tyme Technologies  to Announce  Earnings Per Share
Brokerages Expect Tyme Technologies to Announce Earnings Per Share
Bitcoin Atom  Price Hits $1.06
Bitcoin Atom Price Hits $1.06
TPI Composites  vs. Westport Fuel Systems  Financial Survey
TPI Composites vs. Westport Fuel Systems Financial Survey
Reviewing Aviva  & Its Rivals
Reviewing Aviva & Its Rivals
Guaranty Bancorp  Upgraded to “Buy” by Zacks Investment Research
Guaranty Bancorp Upgraded to “Buy” by Zacks Investment Research


© 2006-2018 Ticker Report. Google+.